Tags

Type your tag names separated by a space and hit enter

Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Minerva Ginecol. 2008 Feb; 60(1):39-51.MG

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting 5-10% of reproductive aged women, about 1 out of 15 women worldwide. Traditionally it was considered as a reproductive disorder showing hyperandrogenism, chronic anovulation and infertility; it is now well accepted that PCOS represents a ''multifaceted'' syndrome with substantial metabolic and cardiovascular long term consequences. Several PCOS women present abdominal adiposity (visceral fat) with a level of peripheral insulin resistance (IR), similar to that present in women with type 2 diabetes, in association with an increased incidence of impaired glucose tolerance. Several cardiovascular risk factors are often related to metabolic alterations, such as dyslipidemia, hypertension, endothelial dysfunction, low grade chronic inflammation, that are present even at early age in PCOS women. Pathogenetic mechanisms of these impairments are not completely clarified yet, but IR appears to play a critical role, such as the key factor linking hypertension, glucose intolerance, obesity, lipid abnormalities and coronary artery disease. In conclusion, although increased incidence of metabolic abnormalities and metabolic disease like type 2 diabetes, and several cardiovascular abnormalities have been widely demonstrated in PCOS women, larger and multicenter trials of long term cardiovascular outcomes are required to better define the incidence of cardiovascular risk and cardiovascular disease in PCOS.

Authors+Show Affiliations

Department of Endocrinology, Parthenope University, Naples, Italy. francescoorio@virgilio.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18277351

Citation

Orio, F, et al. "Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome." Minerva Ginecologica, vol. 60, no. 1, 2008, pp. 39-51.
Orio F, Vuolo L, Palomba S, et al. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol. 2008;60(1):39-51.
Orio, F., Vuolo, L., Palomba, S., Lombardi, G., & Colao, A. (2008). Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecologica, 60(1), 39-51.
Orio F, et al. Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Minerva Ginecol. 2008;60(1):39-51. PubMed PMID: 18277351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic and cardiovascular consequences of polycystic ovary syndrome. AU - Orio,F, AU - Vuolo,L, AU - Palomba,S, AU - Lombardi,G, AU - Colao,A, PY - 2008/2/16/pubmed PY - 2008/6/28/medline PY - 2008/2/16/entrez SP - 39 EP - 51 JF - Minerva ginecologica JO - Minerva Ginecol VL - 60 IS - 1 N2 - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting 5-10% of reproductive aged women, about 1 out of 15 women worldwide. Traditionally it was considered as a reproductive disorder showing hyperandrogenism, chronic anovulation and infertility; it is now well accepted that PCOS represents a ''multifaceted'' syndrome with substantial metabolic and cardiovascular long term consequences. Several PCOS women present abdominal adiposity (visceral fat) with a level of peripheral insulin resistance (IR), similar to that present in women with type 2 diabetes, in association with an increased incidence of impaired glucose tolerance. Several cardiovascular risk factors are often related to metabolic alterations, such as dyslipidemia, hypertension, endothelial dysfunction, low grade chronic inflammation, that are present even at early age in PCOS women. Pathogenetic mechanisms of these impairments are not completely clarified yet, but IR appears to play a critical role, such as the key factor linking hypertension, glucose intolerance, obesity, lipid abnormalities and coronary artery disease. In conclusion, although increased incidence of metabolic abnormalities and metabolic disease like type 2 diabetes, and several cardiovascular abnormalities have been widely demonstrated in PCOS women, larger and multicenter trials of long term cardiovascular outcomes are required to better define the incidence of cardiovascular risk and cardiovascular disease in PCOS. SN - 0026-4784 UR - https://www.unboundmedicine.com/medline/citation/18277351/Metabolic_and_cardiovascular_consequences_of_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -